APO-DIPYRIDAMOLE TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Compra

Scheda tecnica Scheda tecnica (SPC)
10-08-2021

Principio attivo:

DIPYRIDAMOLE

Commercializzato da:

APOTEX INC

Codice ATC:

B01AC07

INN (Nome Internazionale):

DIPYRIDAMOLE

Dosaggio:

50MG

Forma farmaceutica:

TABLET

Composizione:

DIPYRIDAMOLE 50MG

Via di somministrazione:

ORAL

Confezione:

250ML

Tipo di ricetta:

Prescription

Area terapeutica:

MISCELLANEOUS VASODILATATING AGENTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0106621002; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2021-08-12

Scheda tecnica

                                Page 1 of 18
PRODUCT MONOGRAPH
PR
APO-DIPYRIDAMOLE
DIPYRIDAMOLE TABLETS USP
25, 50, 75 AND 100 MG
PR
APO-DIPYRIDAMOLE-SC
DIPYRIDAMOLE SUGAR-COATED TABLETS USP
25, 50 AND 75 MG
CORONARY VASODILATOR
INHIBITOR OF PLATELET ADHESION AND AGGREGATION
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
AUGUST 10, 2021
CONTROL NUMBER: 246833
Page 2 of 18
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT
INFORMATION......................................................................................
3
INDICATIONS AND CLINICAL USES
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
3
ADVERSE
REACTIONS.............................................................................................................
4
DRUG INTERACTIONS
.............................................................................................................
5
DOSAGE AND ADMINISTRATION
.............................................................................................
6
OVERDOSAGE..........................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................
6
STORAGE AND STABILITY
.......................................................................................................
7
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................................. 7
PART II: SCIENTIFIC INFORMATION
...........................................................................................
9
PHARMACEUTICAL INFORMATION
.............................................
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Scheda tecnica Scheda tecnica francese 10-08-2021

Cerca alert relativi a questo prodotto